Neuroimaging

Sam Burnham
Team Leader
Neuroimaging

Our team of engineers and scientists provide the tools to unlock data from images. We apply our science to quantify and interrogate clinical images of the brain, in turn providing biomarkers to diagnose and stage a number of Neurodegenerative diseases.

Neurodegenerative diseases refer to a group of age-related brain illnesses that result in progressive loss of brain tissue and cognitive function. Early detection is now recognized as the critical path to effective treatment for various forms of neurodegenerative diseases, including Alzheimer’s disease, as it may allow interventions prior to widespread tissue loss. The primary pathway for early detection is through identification of neuropathology biomarkers with neuro-imaging modalities. We provide automated quantification of such biomarkers to collaborators at Austin Health, Florey Institute of Neuroscience, McCusker Alzheimer’s Research Foundation (MARF) Edith Cowan University (ECU), Macquarie University for the Australian Imaging and Biomarker and Lifestyle (AIBL), KARVIAH and PISA studies. Our projects develop cutting edge validated methods to acquire and automatically extract information from medical images to improve diagnosis, treatment delivery efficiency, cost-effectiveness and patient quality of life.

Impact on the Health System
Translation of our technologies is key to deliver impact. For instance, quantifying neocortical Aβ-amyloid would not be of value if we hadn’t used this quantification to determine the level of deposition that is associated with risk of disease. We were also able to further that understanding by determining its deposition is a long-protracted process spanning decades. This research has provided key pieces of understanding that have identified a 15-17 year pre-clinical window for preventative treatment in AD resulting in the first preclinical trials.

Our Solutions
Investing of resources in artificial intelligence technologies for automated quantification of imaging biomarkers to ensure that the Neuroimaging team remain at the forefront of the digital disruption and maintain our competitive advantage we are investing resources in artificial intelligence technologies for automated quantification of imaging biomarkers. We are ensuring that we are able to provide high-throughput and harmonised delivery of our science to promote the ever increasing pull for data as we move towards personalised health metrics.

Case Studies

Team Members:

Sam Burnham

Pierrick Bourgeat

Vincent Doré

Ying Xia

Xingjuan Li

 

 

 

 

 

 

 

 

 

 

 

Sam Burnham
Team Leader and senior research scientist using bio-stats to evaluate quantitative imaging metrics to better understand ageing and its associated diseases. Sam has published many articles in high impact journals, presented at world leading forums and holds a number of prestigious awards.
CSIRO Profile

Pierrick Bourgeat
Senior Research Scientist focused on developing tools for PET and MR images quantification. Pierrick also has a keen interest in deep learning techniques.
CSIRO Profile

Vincent Doré
Senior Research Scientist interested in PET quantification, surface projection and statistical population analysis. Vincent is based in the nuclear department of Austin Hospital to collaborate with clinicians principally on the Australian Imaging, Biomarker and Lifestyle (AIBL) study and has been there since September 2012. His role is to develop visualisation and quantification tools to facilitate clinicians interpretation of PET scans.
CSIRO Profile

Ying Xia
Postdoctoral Fellow, develops methods to analyse medical data to understand the association and dissimilarities between vascular pathology and Alzheimer’s disease.
CSIRO Profile

Xingjuan Li
Postdoctoral Fellow focusing on the early prediction of Alzheimer’s disease using deep learning techniques. Xingjuan’s research interests include artificial intelligence, data analytics and computational neuroscience.